Tag Archive for: cancer therapy

The biotech company has bought the global rights to an investigational oral CDK2 inhibitor from Ensem Therapeutics in a licensing agreement valued at up to $1.33 billion if all milestones are met.

The U.S. health regulator will not meet its Dec. 16 deadline on the use of Bristol Myers Squibb and partner 2seventy bio’s blood cancer therapy in earlier lines of treatment as it plans to seek the advice of independent experts before making a decision, the companies said.

The three drug candidates to be developed with Merck belong to the class known as antibody drug conjugates (ADC) and are in various stages of clinical development for the treatment of multiple solid cancer tumors.

Novocure said today that its therapy failed in a late-stage trial to meet the main goal of improving survival rates in patients with a type of ovarian cancer.

The company said its therapy involving cancer drug Keytruda in combination with chemotherapy met the main goal of a late-stage study for treating a type of gastric cancer.